Huang M.-C.Kao C.-F.Chiu C.-C.PO-HSIU KUOChen P.-Y.Lu M.-L.2020-11-182020-11-1820140271-0749https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891747323&doi=10.1097%2fJCP.0b013e3182a95b20&partnerID=40&md5=f49983a0716333b64d951582e95bbd4fhttps://scholars.lib.ntu.edu.tw/handle/123456789/521079[SDGs]SDG3clozapine; fto protein; neuroleptic agent; olanzapine; oxygenase; unclassified drug; blood chemistry; blood pressure; body mass; drug efficacy; drug safety; drug tolerability; fat mass; follow up; gene expression; genetic association; genetic susceptibility; genetic variability; genotype; human; laboratory test; letter; mental patient; metabolic disorder; metabolic parameters; metabolic syndrome X; obesity; priority journal; risk assessment; risk factor; schizophrenia; waist circumference; Adult; Aged; Antipsychotic Agents; Biological Markers; Blood Glucose; Female; Genetic Predisposition to Disease; Genetic Variation; Humans; Insulin; Lipids; Male; Middle Aged; Obesity; Phenotype; Proteins; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain; Young AdultThe genetic association of fto variants with metabolic traits in patients with schizophrenia may be modified by antipsychoticsletter10.1097/JCP.0b013e3182a95b20J. Clin. Psychopharmacol.